Ascendis Pharma A/S (ASND) Report Analysis
Corporate Events
Ascendis Pharma A/S Approves to Amend the Articles of Association
2022-06-02 20:02:00
Ascendis Pharma A/S shareholders adopted the proposal of the Board to amend the Articles of Association by renewing the authorization to the Board to obtain loan against issuance of convertible bonds which gives the right to subscribe new shares in the Company, at its annual general meeting held on 30 May 2022.
Ascendis Pharma A/S Announces Management Changes
2022-05-23 12:00:00
Ascendis Pharma A/S announced new Endocrinology commercial leadership appointments following the retirement of Global Chief Commercial Officer Jesper Høiland: Having established U.S. commercial operations, Jesper Høiland will retire from his position at Ascendis Pharma to return to Denmark with his family. Mr. Høiland joined Ascendis as Senior Vice President and Global Chief Commercial Officer in May 2020, bringing more than 25 years of senior leadership experience in operations, commercialization, and global marketing to his role. Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology. Mr. Kelly joined Ascendis in September 2020 as Vice President of Sales, U.S., where he has been leading the sales team to successfully increase awareness and build demand during the launch of SKYTROFA (lonapegsomatropin-tcgd), the company's first commercial product. Mr. Kelly has over 20 years of healthcare industry and sales experience and an exceptional track record of growing sales, developing people, and carefully listening to customers’ needs. Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology. Mr. Holmes joined Ascendis in 2018 as Vice President, Commercial Analytics, where he has been responsible for building Ascendis' commercial analytics capabilities and for creating the Ascendis Signature Access Program to support patients, caregivers, physicians, and payers.
Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent
2022-05-23 12:00:00
Ascendis Pharma A/S announced that results from VISEN Pharmaceuticals’ Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharma’s earlier multi-national Phase 3 trial. VISEN Pharmaceuticals’ Phase 3 trial achieved its primary endpoint, with pediatric GHD patients treated with once-weekly TransCon hGH demonstrating greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone. In both Ascendis Pharma’s and VISEN Pharmaceuticals’ Phase 3 trials, TransCon hGH – now approved in both the U.S. and EU as a once-weekly treatment for pediatric GHD – demonstrated statistical non-inferiority and superiority on the primary endpoint with comparable safety and tolerability to daily growth hormone.
Ascendis Pharma A/S, Q1 2022 Earnings Call, May 11, 2022
2022-05-04 20:05:00
Ascendis Pharma A/S, Q1 2022 Earnings Call, May 11, 2022
Ascendis Pharma A/S, Annual General Meeting, May 30, 2022
2022-05-02 10:25:00
Ascendis Pharma A/S, Annual General Meeting, May 30, 2022, at 14:00 Central European Standard Time. Location: Mazanti-Andersen, Amaliegade 10 DK-1256 Copenhagen K Denmark Agenda: To elect the Chairman of the meeting; to report on the company’s activities during the past year; to present the audited annual report with auditor’s statement for approval and discharge of the Board of Directors and management; to consider resolution on application of profits or covering of losses as per the adopted annual report ; to elect Board members; to elect state-authorized public auditor; and to consider any proposals from the Board of Directors and/or shareholders.
Ascendis Pharma A/S Announces Resignation of James I. Healy as Independent Member of Board of Directors, Effective from May 30, 2022
2022-05-02 10:19:00
On May 2, 2022, Dr. James I. Healy submitted his resignation as an independent member of the Ascendis Pharma A/S board of directors and as a member of the audit committee of the Board and the nominating and corporate governance committee of the Board, effective May 30, 2022. Dr. Healy’s resignation was not due to any disagreement with the Company, the Board or the management of the Company.
Ascendis Pharma A/S - Special Call
2022-05-01 11:00:00
An analysis of the subset of participants who completed the trial, with information on difference between Virtual last visit height and target height, and difference between height SDS at last visit and average parental height SDS
Ascendis Pharma A/S Presents at 14th Kempen Life Sciences Conference, Apr-20-2022
2022-03-29 06:52:00
Ascendis Pharma A/S Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.
Ascendis Pharma A/S has completed a Fixed-Income Offering in the amount of $500 million.
2022-03-24 00:00:00
Ascendis Pharma A/S has completed a Fixed-Income Offering in the amount of $500 million. Security Name: 2.25% Senior Unsecured Notes due April 1, 2028 Security Type: Corporate Bond/Note (Convertible) Principal Amount: $500 million Price\Range: 100% Security Features: Convertible; Senior; Unsecured Coupon Type: Fixed Transaction Features: Rule 144A
Ascendis Pharma A/S has announced a Fixed-Income Offering.
2022-03-23 00:00:00
Ascendis Pharma A/S has announced a Fixed-Income Offering. Security Name: Senior Unsecured Notes due April 1, 2028 Security Type: Corporate Bond/Note (Convertible) Principal Amount: $500 million Security Features: Convertible; Senior; Unsecured Transaction Features: Rule 144A
Ascendis Pharma A/S Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:40 AM
2022-03-22 05:03:00
Ascendis Pharma A/S Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:40 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Jan Moller Mikkelsen, President, CEO, Member of Executive Board & Executive Director, Scott T. Smith, CFO, Senior VP & Member of Executive Board.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Rare Disease Development Programs
2021-12-14 13:00:00
Ascendis Pharma A/S planed to provide an update on two of its investigational endocrinology rare disease development programs, TransCon PTH for hypoparathyroidism, and TransCon CNP for achondroplasia, and on one of its investigational oncology product candidates, TransCon TLR7/8 Agonist at the Company’s virtual R&D Program Update. Ascendis’ management outlined continued clinical advancement on each of the three rare disease development programs. Highlights include: Update from ongoing TransCon PTH development program: Reviewed clinical data from ongoing Phase 2 PaTH Forward Trial. Topline results from the Phase 3 PaTHway Trial expected in First Quarter 2022. Planned NDA submission in Third Quarter 2022 for the treatment of adults with hypoparathyroidism. Topline results from the PaTHway Japan Trial expected in Third Quarter 2022. Planned MAA submission in Fourth Quarter 2022 for the treatment of adults with hypoparathyroidism. Initiation of the pediatric hypoparathyroidism program planned for Fourth Quarter 2022.
Ascendis Pharma A/S has filed a Shelf Registration in the amount of $396.435516 million.
2021-12-08 00:00:00
Ascendis Pharma A/S has filed a Shelf Registration in the amount of $396.435516 million. Security Name: Ordinary Shares Securities Offered: 2,773,246 Transaction Features: ESOP Related Offering
Ascendis Pharma A/S - Special Call
2021-12-07 22:41:00
To discuss updates on Ascendis Pharma’s endocrinology rare disease development programs and Ascendis’ oncology product candidate TransCon TLR7/8 Agonist
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial
2021-11-18 21:42:00
Ascendis Pharma A/S announced top-line results from Week 84 of the Company’s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in adult patients with hypoparathyroidism (HP). TransCon PTH is an investigational once-daily prodrug of parathyroid hormone (PTH) designed to restore physiologic levels of PTH 24 hours a day. The week 84 data showed that subjects treated with TransCon PTH had both mean serum calcium levels and urinary calcium excretion that remained stable and in the normal range and that most subjects (93%) continued to be free from taking active vitamin D and were taking < 600 mg/day of calcium supplements. After an initial screening and baseline assessment period, patients in the Phase 2 PaTH Forward Trial were randomized to blinded treatment with TransCon PTH at 15, 18, or 21 µg/day or placebo for 4 weeks, followed by a switch to open label treatment, during which physicians could optimize dosing of TransCon PTH to meet individual treatment objectives. Key Findings at Week 84 of the Phase 2 PaTH Forward Trial: 58 out of the 59 original trial participants continued open-label treatment with TransCon PTH; Mean serum calcium levels remained stable and in the normal range; All study subjects discontinued active vitamin D supplements in the earliest weeks of the trial and have remained off it since then. In addition, 93% of study subjects were taking calcium supplements <600 mg/day Mean urinary calcium excretion remained stable and in the normal range; TransCon PTH was well-tolerated at all doses administered. No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events (TEAEs) led to discontinuation of study drug.
Ascendis Pharma A/S Elects Rafaèle Tordjman as A Class II Director
2021-11-18 21:01:00
Ascendis Pharma A/S announced that at its EGM held on November 18, 2021, the shareholders elected Rafaèle Tordjman as a Class II director, with the term for such board member to expire at the annual general meeting of the company to be held in 2022.
Ascendis Pharma A/S Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 03:55 PM
2021-11-17 21:05:00
Ascendis Pharma A/S Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 03:55 PM.
Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022
2021-11-13 00:00:00
Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.
Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency
2021-11-12 12:22:00
Ascendis Pharma A/S announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization for Lonapegsomatropin Ascendis Pharma (TransCon hGH). TransCon hGH is a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin (also called human growth hormone, or hGH), indicated for growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD). The European Commission final decision on the company’s Marketing Authorisation Application (MAA) for TransCon hGH is expected within 67 days after the positive opinion, or by the end of January 2022. The CHMP opinion is based on results submitted in the MAA from the Company’s Phase 3 heiGHt, fliGHt and enliGHten trials, which collectively treated more than 300 pediatric patients diagnosed with GHD. In 2020, Ascendis Pharma received a positive opinion from the Paediatric Committee of the European Medicines Agency for its TransCon hGH Paediatric Investigation Plan, based on the non-clinical safety program as well as data from the three Phase 3 clinical trials included in the MAA. Earlier this year, the U.S. Food & Drug Administration approved TransCon hGH – marketed in the U.S. under the brand name SKYTROFA® (lonapegsomatropin-tcgd) – for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb.) and have growth failure due to inadequate secretion of endogenous growth hormone. Ascendis Pharma is also developing TransCon hGH in Japan, and separately in China through VISEN Pharmaceuticals. Pediatric GHD is a serious orphan disease caused when the pituitary gland does not produce enough growth hormone. Children with GHD are not only characterized by short stature; they also may experience metabolic abnormalities, psychosocial challenges, and an overall poor quality of life. For decades, the standard of care for GHD has been a daily subcutaneous injection of hGH to improve growth and overall endocrine health.
Tranche Update on Ascendis Pharma A/S (NasdaqGS:ASND)'s Equity Buyback Plan announced on September 29, 2021.
2021-11-10 16:12:00
From September 29, 2021 to November 10, 2021, the company has repurchased 154,837 shares, representing 0.29% for $25 million. With this, the company has completed the repurchase of 154,837 shares, representing 0.29% for $25 million under the buyback announced on September 29, 2021.
Ascendis Pharma A/S's Equity Buyback announced on September 29, 2021, has expired with 154,837 shares, representing 0.29% for $25 million.
2021-11-10 00:00:00
The company expired its plan on November 10, 2021.
Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon TLR7/8 Agonist Oncology Program at SITC 2021
2021-11-09 13:00:00
Ascendis Pharma A/S announced two poster presentations featuring new non-clinical data for its investigational TransCon™ TLR7/8 Agonist product candidate at SITC 2021, the annual meeting for the Society for Immunotherapy of Cancer taking place virtually and in person November 10-14 in Washington, D.C. The data show that, as designed, TransCon TLR7/8 Agonist, which leverages the Company’s innovative TransCon hydrogel technology, provides sustained activation of both innate and adaptive immune mechanisms with low systemic cytokine levels. TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines for weeks or months with a single intratumoral injection. Ascendis Pharma is currently conducting a Phase 1/2 study, called the transcendIT-101 Study (ClinicalTrials.gov Identifier: NCT04799054), to evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion cohorts. The primary objectives are to evaluate safety and tolerability and to define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.
Ascendis Pharma A/S, Q3 2021 Earnings Call, Nov 10, 2021
2021-11-03 12:00:00
Ascendis Pharma A/S, Q3 2021 Earnings Call, Nov 10, 2021
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022
2021-10-29 14:57:00
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.
Ascendis Pharma A/S, Special/Extraordinary Shareholders Meeting, Nov 18, 2021
2021-10-21 10:06:00
Ascendis Pharma A/S, Special/Extraordinary Shareholders Meeting, Nov 18, 2021, at 14:00 Central European Standard Time. Location: Mazanti-Andersen Korsø Jensen, Amaliegade 10, DK-1256 Copenhagen K Denmark Agenda: To consider the election of Chairman of the Meeting; to consider the election of new Board Member; and to consider the authorisation of the chairman of the meeting.
Ascendis Pharma A/S Announces U.S. Commercial Launch of Skytrofa the First and Only FDA Approves Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
2021-10-15 12:00:00
Ascendis Pharma A/S announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacies across the United States.
Ascendis Pharma A/S Announces Presentations for TransCon PTH and TransCon CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting
2021-09-30 20:01:00
Ascendis Pharma A/S announced presentations featuring new data about its investigational TransCon PTH product candidate at the American Society for Bone & Mineral Research (ASBMR) 2021 Annual Meeting, being held October 1-4 virtually and in-person in San Diego. Presentations will also include an overview of baseline demographics from the Ascendis Pharma-sponsored natural history study of children with achondroplasia. Hypoparathyroidism (HP) is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) which plays a critical role in controlling systemic calcium, phosphate, and calcitriol (active vitamin D) levels and is essential to many key biological functions. HP affects approximately 400,000 patients in the United States, Europe, Japan, South Korea and Greater China, the majority of whom develop the condition following damage or accidental removal of the parathyroid glands during thyroid surgery. Patients often experience decreased quality of life. In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache. Over the long term, this complex disorder can increase risk of major complications, such as extraskeletal calcium depositions occurring within the brain, lens of the eye, and kidneys, which can lead to impaired renal function. HP remains among the few hormonal insufficiency states without an approved replacement therapy that restores the missing hormone at physiologic levels. Standard of care with active vitamin D analogs and calcium supplementation does not fully control the disease and may contribute to risk of renal disease. As a result, patients with HP have an estimated 4-fold to 8-fold greater risk of renal disease compared to healthy controls.
Ascendis Pharma A/S (NasdaqGS:ASND) announces an Equity Buyback for 300,000 shares, for $25 million.
2021-09-29 21:01:00
Ascendis Pharma A/S (NasdaqGS:ASND) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 American Depositary Shares, for $25 million. The purpose of the program is to acquire ADS needed in connection with the company’s planned share-based incentive program. The program is expected to end no later than December 31, 2021. The company expects to fund the program through its existing cash or cash equivalents.
Ascendis Pharma A/S authorizes a Buyback Plan.
2021-09-29 00:00:00
The Board of Directors of Ascendis Pharma A/S has authorized a buyback plan on September 29, 2021. The program will commence from November 1, 2021.
Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
2021-09-22 20:27:00
Ascendis Pharma A/S announced 58-week BMD data from central lab reading in the PaTH Forward Trial, a global phase 2 trial of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism (HP). Anatomic region, n, Baseline, Week 26, Week 58 includes: Lumbar spine, (L1-L4), 42, 1.6, 1.0, 0.9; Femoral neck,43, 1.0, 0.5, 0.5; Total hip, 43,1.0,0.6, 0.5; Forearm/1/3 radius, 41, 0.3, 0.3, 0.3 respectively. TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) in development as a treatment for adult hypoparathyroidism (HP), designed to restore PTH at physiologic levels for 24 hours each day to address both the short-term symptoms and long-term complications of the disease. TransCon PTH has been granted Orphan drug status in the United States, European Union, and Japan. HP is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) which plays a critical role in controlling systemic calcium, phosphate, and calcitriol (active vitamin D) levels and is essential to many key biological functions. HP affects approximately 400,000 patients in the United States, Europe, Japan, South Korea and Greater China, the majority of whom develop the condition following damage or accidental removal of the parathyroid glands during thyroid surgery. Patients often experience decreased quality of life. In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache. Over the long term, this complex disorder can increase risk of major complications, such as extraskeletal calcium depositions occurring within the brain, lens of the eye, and kidneys, which can lead to impaired renal function. HP remains among the few hormonal insufficiency states without an approved replacement therapy that restores the missing hormone at physiologic levels. Standard of care with active vitamin D analogs and calcium supplementation does not fully control the disease and may contribute to risk of renal disease. As a result, patients with HP have an estimated 4-fold to 8-fold greater risk of renal disease compared to healthy controls.
Ascendis Pharma A/S Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 12:30 PM
2021-09-07 21:09:00
Ascendis Pharma A/S Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 12:30 PM. Venue: New Windsor, United States.
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ß/? Clinical Program
2021-09-07 20:59:00
Ascendis Pharma A/S announced the submission of an investigational new drug (IND) application with the U.S. Food & Drug Administration (FDA) to initiate IL ßelie?e (I’ll Believe) Trial, a phase 1/2 clinical trial to evaluate TransCon IL-2 ß/? in patients with advanced cancer. TransCon IL-2 ß/? is an investigational long-acting prodrug designed to improve cancer immunotherapy by sustained exposure to an IL-2 variant that selectively activates the IL-2Rß/?, with minimal binding to IL-2Ra.
Ascendis Pharma A/S has completed a Follow-on Equity Offering in the amount of $400 million.
2021-09-01 00:00:00
Ascendis Pharma A/S has completed a Follow-on Equity Offering in the amount of $400 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 2,500,000 Price\Range: $160 Discount Per Security: $8
Credit Suisse Securities (USA) LLC has been added as the Co-Lead Underwriter for Ascendis Pharma A/S's $400 million Follow-on Equity Offering.
2021-09-01 00:00:00
Credit Suisse Securities (USA) LLC has been added as the Co-Lead Underwriter for Ascendis Pharma A/S's $400 million Follow-on Equity Offering.
Wells Fargo Securities, LLC has been added as the Co-Lead Underwriter for Ascendis Pharma A/S's $400 million Follow-on Equity Offering.
2021-09-01 00:00:00
Wells Fargo Securities, LLC has been added as the Co-Lead Underwriter for Ascendis Pharma A/S's $400 million Follow-on Equity Offering.
Certain Ordinary Shares of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 17-OCT-2021.
2021-09-01 00:00:00
Certain Ordinary Shares of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 17-OCT-2021. These Ordinary Shares will be under lockup for 46 days starting from 1-SEP-2021 to 17-OCT-2021. Details: The company's directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons, with limited exceptions, for a period of 45 days after the date of this prospectus supplement, may not, without the prior written consent of J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and SVB Leerink LLC, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend or otherwise transfer or dispose of any Lock-Up Securities, or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, enter into any hedging, swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of ADSs, ordinary shares or other securities, in cash or otherwise, or publicly disclose the intention to do any of the foregoing.
Certain Warrants of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 17-OCT-2021.
2021-09-01 00:00:00
Certain Warrants of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 17-OCT-2021. These Warrants will be under lockup for 46 days starting from 1-SEP-2021 to 17-OCT-2021. Details: The company's directors and executive officers have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons, with limited exceptions, for a period of 45 days after the date of this prospectus supplement, may not, without the prior written consent of J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and SVB Leerink LLC, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend or otherwise transfer or dispose of any Lock-Up Securities, or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, enter into any hedging, swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of ADSs, ordinary shares or other securities, in cash or otherwise, or publicly disclose the intention to do any of the foregoing.
Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $400 million.
2021-08-31 00:00:00
Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $400 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 2,592,688 Price\Range: $154.280037
Ascendis Pharma Announces U.S. Food and Drug Administration Approval of SKYTROFA
2021-08-25 19:24:00
Ascendis Pharma A/S announced that the U.S. Food and Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). As a once-weekly injection, SKYTROFA is the first FDA approved product that delivers somatropin (growth hormone) by sustained release over one week. Growth hormone deficiency is a serious orphan disease characterized by short stature and metabolic complications. In GHD, the pituitary gland does not produce sufficient growth hormone, which is important not only for height but also for a child’s overall endocrine health and development. The approval includes the new SKYTROFA® Auto-Injector and cartridges which, after first removed from a refrigerator, allow families to store the medicine at room temperature for up to six months. With a weekly injection, patients switching from injections every day can experience up to 86% fewer injection days per year. In connection with the commercialization of SKYTROFA, the company is committed to offering a full suite of patient support programs, including educating families on proper injection procedures for SKYTROFA as the first once-weekly treatment for children with GHD. The FDA approval of SKYTROFA was based on results from the phase 3 heiGHt Trial, a 52-week, global, randomized, open-label, active-controlled, parallel-group trial that compared once-weekly SKYTROFA to daily somatropin (Genotropin®) in 161 treatment-naïve children with GHDii. The primary endpoint was, AHV at 52 weeks for weekly SKYTROFA and daily hGH treatment groups. Other endpoints included adverse events, injection-site reactions, incidence of anti-hGH antibodies, annualized height velocity, change in height SDS, proportion of subjects with IGF-1 SDS (0.0 to +2.0), PK/PD in subjects < 3 years, and preference for and satisfaction with SKYTROFA. At week 52, the treatment difference in AHV was 0.9 cm/year (11.2 cm/year for SKYTROFA compared with 10.3 cm/year for daily somatropin) with a 95% confidence interval [0.2, 1.5] cm/year. The primary objective of non-inferiority in AHV was met for SKYTROFA in this trial and further demonstrated a higher AHV at week 52 for lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD. No serious adverse events or discontinuations related to SKYTROFA were reported. Most common adverse reactions (= 5%) in pediatric patients include: infection, viral (15%), pyrexia (15%), cough (11%), nausea and vomiting (11%), hemorrhage (7%), diarrhea (6%), abdominal pain (6%), and arthralgia and arthritis (6%)ii. In addition, both arms of the study reported low incidences of transient, non-neutralizing anti-hGH binding antibodies and no cases of persistent antibodies.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Ascendis Pharma A/S, Q2 2021 Earnings Call, Aug 25, 2021
2021-08-17 20:17:00
Ascendis Pharma A/S, Q2 2021 Earnings Call, Aug 25, 2021
Ascendis Pharma A/S Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 09:10 AM
2021-08-06 11:05:00
Ascendis Pharma A/S Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 09:10 AM.
Ascendis Pharma A/S Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-12-2021 11:00 AM
2021-08-06 11:05:00
Ascendis Pharma A/S Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-12-2021 11:00 AM. Speakers: Patti Bank, Investor Relations, Scott T. Smith, CFO, Senior VP & Member of Executive Board, Tim Lee, Senior Director, Investor Relations.
Ascendis Pharma A/S Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 02:40 PM
2021-07-22 14:24:00
Ascendis Pharma A/S Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 02:40 PM. Speakers: Patti Bank, Scott T. Smith, CFO, Senior VP & Member of Executive Board, Tim Lee, Senior Director, Investor Relations.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update
2021-07-06 12:00:00
Ascendis Pharma A/S announced it has reached the target enrollment in the phase 3 PaTHway Trial, a trial evaluating the safety, tolerability, and efficacy of TransCon PTH (palopegteriparatide) in addition to providing a comprehensive global clinical program update. The PaTHway Trial is a phase 3, randomized, double-blind, placebo-controlled trial in North America and Europe evaluating the safety, tolerability, and efficacy of palopegteriparatide in adults with HP. The primary efficacy endpoint is the proportion of subjects with albumin-adjusted serum calcium within the normal range, and independent from active vitamin D and therapeutic doses of calcium (= 600 mg/day) at 26 weeks. If successful, Ascendis expects to submit an NDA to the U.S. Food and Drug Administration (FDA) in mid-2022 and subsequently submit a Marketing Authorisation Application to the European Medicines Agency. Ascendis also announced the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) acceptance of the clinical trial notification for the PaTHway Japan Trial, a single-arm, phase 3 trial of palopegteriparatide in a minimum of 12 Japanese subjects with HP. Subjects will start with an 18 µg dose of palopegteriparatide and be followed over a 26-week period during which they will be titrated to an optimal dose. In addition, MHLW granted ODD to palopegteriparatide for the treatment of HP. In Japan, ODD is granted to therapies intended for use in less than 50,000 patients in Japan and for which significant unmet medical need exists. The designation is granted by the MHLW based on the opinion of the Pharmaceutical Affairs and Food Sanitation Council. In Greater China, VISEN recently announced that they obtained the IND approval from the Center for Drug Evaluation of the National Medical Products Administration for the phase 3 China clinical trial (PaTHway China Trial) of TransCon PTH on June 1, 2021 and is soon expected to initiate the study of TransCon PTH in patients with HP in China. The design of the PaTHway China Trial mirrors the design of the PaTHway Trial. All subjects from phase 3 PaTHway trials in North America, Europe, Japan and Greater China will be eligible to enter into open-label extensions to collect long-term follow-up data.
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021
2021-06-29 20:28:00
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.
Fundamental Summary
The financials published by Ascendis Pharma for Q1 were weak and discouraging. Their negative income, growth, and value factors indicate that the company is finding it increasingly difficult to produce impressive numbers. These results indicate a weak growth potential for Ascendis Pharma's stock's price moving forward. As such, Ascendis Pharma received an overall score of 60 and a UNDERPERFORM recommendation.
Ascendis Pharma reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EUR 6.83 million compared to EUR 0.746 million a year ago. Net loss was EUR 125.5 million compared to EUR 62.79 million a year ago. Basic loss per share from continuing operations was EUR 2.21 compared to EUR 1.17 a year ago.
Business Description
Ascendis Pharma, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector Overview
Ascendis Pharma is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Ascendis Pharma's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -60.5 | -35.8% | 46 | |
| Net Cashflow | 260.6 | 288.5% | 48 | |
| Capital Expenditure | -23.5 | 0.9% | 77 | |
| Asset Turnover | 0.0 | 57.1% | 98 | |
| Free Cashflow | -8.8 | -9.5% | 59 |
* All values are TTM
The below chart reflects Ascendis Pharma's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Ascendis Pharma's peer average final assessment score stands on 59.0, Ascendis Pharma's score is 60.
- ASND
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Ascendis Pharma's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Ascendis Pharma's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.
5D MA
91.31
50D MA
90.42
200D MA
122.96
MACD
0.24
RSI
51.06
STOCH
88.18
Balance Sheet Analysis
Ascendis Pharma appears likely to maintain its strong balance sheet metrics and momentum going forward. Ascendis Pharma did a great job related to cash and cash equivalents this period, which stood at 755.6, representing a 69.3% change from the previous filing. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. The company's cash and cash equivalents movement, therefore, received a grade of 94. Also, Ascendis Pharma reported solid equity numbers this period. At filing, equity was reported as 672.8, representing -23.9% change from the previous period. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly more impressive than its peers and competitors. Therefore, its equity movement component earned a score of 85. On the other hand, Liabilities, jumped out as looking problematic. At filing, Ascendis Pharma's liabilities were 704.4, representing a 250.0% change from the previous period. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Therefore, we rated their liabilities movement with a score of 51. Therefore, we scored the company's balance sheet a 68.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 1,377.2 | 26.9% | 70 |
| Liabilities | 704.4 | 250.0% | 51 |
| Price to Book | 6.7 | -12.1% | 54 |
| Cash & Equivalents | 755.6 | 69.3% | 94 |
| Equity | 672.8 | -23.9% | 85 |
The below chart describes Ascendis Pharma's performance as reflected on its balance sheet with respect to its peers. While Ascendis Pharma received a balance sheet score of 68, the average of its peers stands on 61.0.
- ASND
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 17 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 19 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 22 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Ascendis Pharma's recently published income statement conveys disappointing growth, particularly with respect to Revenue Efficiency and Return Factors metrics. Ascendis Pharma reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 13.9 and represented 78.2% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 38. Also, Ascendis Pharma's reported return on equity (ROE) ratio was -60.5, representing a change of -35.8%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Consequently, their return factors received a grade of 46. That said, one metric, EBITDA, stood out as strongly positive. Ascendis Pharma's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -439.5, which represents a -0.6% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. The company's EBITDA movement, therefore, received a grade of 68. Therefore, it received a cautionary score of 54.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -439.5 | -0.6% | 68 |
| Total Revenues | 13.9 | 78.2% | 38 |
| Return on Equity | -60.5 | -35.8% | 46 |
The below chart describes Ascendis Pharma's performance as reflected on its income statement with respect to its peers. While Ascendis Pharma received a income statement score of 54 , the average of its peers stands on 64.0.
- ASND
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 17 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 22 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Ascendis Pharma appears likely to maintain its strong cash flow metrics and momentum going forward. Ascendis Pharma is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.0, representing a 57.1% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Therefore, its asset turnover movement earned a score of 98. Also, Ascendis Pharma's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -23.5, which represents a 0.9% change from the last period. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Therefore, its CapEx movement component earned a score of 77. However, one discouraging result, Net Cash Flow, stood out. Ascendis Pharma's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as 260.6 and represented a 288.5% change from the previous period. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Ascendis Pharma's stock price going forward. Consequently, their net cash flow movement received a grade of 48. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 62.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 260.6 | 288.5% | 48 |
| Capital Expenditure | -23.5 | 0.9% | 77 |
| Asset Turnover | 0.0 | 57.1% | 98 |
| Free Cashflow | -8.8 | -9.5% | 59 |
The below chart describes Ascendis Pharma's performance as reflected on its cash flow with respect to its peers. While Ascendis Pharma received a cash flow score of 62, the average of its peers stands on 60.0.
- ASND
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 17 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 22 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.